Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

September 30, 2031

Study Completion Date

September 30, 2031

Conditions
NSCLC Stage IVNSCLC, Stage III
Interventions
DRUG

Repotrectinib

Repotrectinib 160 mg BID, until progression or unacceptable toxicity

Trial Locations (20)

Unknown

RECRUITING

CH Aix-en-Provence, Aix-en-Provence

RECRUITING

AP-HM, Marseille

RECRUITING

HIA Sainte Anne, Toulon

RECRUITING

CHU Angers, Angers

RECRUITING

CHU Bordeaux, Bordeaux

RECRUITING

CHU Brest, Brest

RECRUITING

Centre François Baclesse, Caen

RECRUITING

CH Chambéry, Chambéry

RECRUITING

Hôpitaux civils de Colmar, Colmar

RECRUITING

CHI Créteil, Créteil

RECRUITING

CHD Vendée, La Roche-sur-Yon

RECRUITING

CHRU Lille, Lille

RECRUITING

CHU Limoges, Limoges

RECRUITING

Hospices Civils de Lyon, Lyon

RECRUITING

CH Cornouaille, Quimper

RECRUITING

CHU Rennes, Rennes

RECRUITING

CHU Rouen, Rouen

RECRUITING

Hôpital Foch, Suresnes

RECRUITING

CHU Toulouse, Toulouse

RECRUITING

Hôpitaux Nord-Ouest, Villefranche-sur-Saône

All Listed Sponsors
collaborator

Groupe Francais De Pneumo-Cancerologie

OTHER

collaborator

Hospices Civils de Lyon

OTHER

lead

Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer

OTHER